Chemotherapy is effective in the treatment of many pediatric brain tumors. It offers benefits such as stabilizing disease, reducing radiation dose as well as delaying or eliminating the need for radiation therapy. For several tumor types, chemotherapy has shown improved survival. Agents used in pediatric brain tumors include alkylators, topoisomerase inhibitors, antimetabolites, and plant alkaloids. Temozolomide and bevacizumab are among emerging new therapies that have shown encouraging preliminary results and are being further researched. The clinical use and acute toxicities of commonly used chemotherapy agents are discussed. Finally, intrathecal and intra-Ommaya therapies aimed at overcoming the blood–brain barrier are reviewed.
KeywordsChemotherapy Acute toxicities Mode of delivery Blood–brain barrier
- 2.Gajjar A, Chintagumpala M, Ashley D, Kellie D, Kun LE, Merchant TE, et al. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial. Lancet Oncol. 2006;7:813–20.CrossRefPubMedGoogle Scholar
- 15.von Bueren AO, von Hoff K, Pietsch T, Gerber NU, Warmuth-Metz M, Deinlein F, et al. Treatment of young children with localized medulloblastoma by chemotherapy alone: results of the prospective, multicenter trial HIT 2000 confirming the prognostic impact of histology. Neuro Oncol. 2011;13:669–79.CrossRefGoogle Scholar
- 20.Gururangan S, Chi SN, Poussaint TY, Onar-Thomas A, Gilbertson RJ, Vajapeyam S, et al. Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumour Consortium study. J Clin Oncol. 2010;28:3069–75.CrossRefPubMedCentralPubMedGoogle Scholar
- 24.Slavc I, Schuller E, Falger J, Gunes M, Pillwein K, Czech T, Dietrich W, Rossler K, Dieckmann K, Prayer D, Hainfellner J. Feasibility of long-term intraventricular therapy with mafosfamide (n = 26) and etoposide (n = 11): experience in 26 children with disseminated malignant brain tumours. J Neurooncol. 2003;64:239–47.CrossRefPubMedGoogle Scholar